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Aim To assess serum uric acid (SUA) levels determined on 
admission as a potential predictor of short-term mortality 
and long-term survival in acute myocardial infarction (AMI) 
patients.
Method Data for this retrospective prognostic study were 
drawn from the patient database of the Varaždin County 
General Hospital in Varaždin, Croatia. We included consec-
utive patients with verified AMI admitted within 48 hours 
since the symptom onset during the period between 1 
January 1996 and 31 December 2001. Long-term surviv-
al/mortality data were collected through direct contacts 
with patients and search of the community death regis-
tries. Relative risks (RR) and hazard ratios (HR) by 10 µmol/
L increase in SUA were determined using modified Pois-
son regression with robust error variance and proportional 
hazard regression, respectively.
Results A total of 621 patients (age 27-90 years, 64.7% men, 
77.5% AMI with ST elevation, SUA 63-993 µmol/L) were in-
cluded. Higher SUA on admission was independently as-
sociated with higher in-hospital mortality (RR, 1.016; 95% 
confidence interval [CI], 1.001-1.031, P = 0.043) and high-
er thirty-day mortality (RR, 1.016; 95% CI, 1.003-1.029, 
P = 0.018). Considered covariates were demographics, pre-
index event cardiovascular morbidity and treatment, on-
admission serum creatinine, total cholesterol and triglycer-
ides, AMI characteristics, and peak creatine phosphokinase. 
Higher SUA on admission was also independently associat-
ed with poorer long-term survival (ie, higher all-cause mor-
tality) (HR, 1.105; 95% CI, 1.020-1.195, P = 0.010). Considered 
covariates were demographics, laboratory variables on ad-
mission, AMI characteristics, peak creatine phosphokinase, 
acute complications, and treatment at discharge.
Conclusion Higher serum uric acid determined on admis-
sion is associated with higher in-hospital mortality and thir-
ty-day mortality and poorer long-term survival after AMI.
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In humans, uric acid (UA) is the end product of purine ca-
tabolism (1). Its serum levels (SUA), governed by the pro-
duction (liver) and elimination (mainly the kidney) rates, 
are influenced by genetically determined factors (eg, activ-
ity of synthesizing enzymes or renal transporter systems), 
racial and demographic characteristics (eg, sex, gonadal 
function in women, obesity), diet (eg, purine-rich foods, 
fructose, alcohol), habits (eg, SUA is lower in smokers and 
increases after quitting), morbidity (eg, heart or renal fail-
ure, malignancies), and medications (eg, diuretics, cyto-
toxic agents) (1-4). The role of SUA in cardiovascular and 
renal diseases has been intensively investigated, although 
not without controversy (5). On the molecular and cellular 
level, UA exerts a number of effects of potential interest: it 
is one of the most important antioxidants in plasma, but 
at high concentrations it may promote oxidative stress; it 
may induce endothelial dysfunction and vascular smooth 
muscle cell proliferation in vitro, platelet aggregation, and 
microinflammation; increased UA causes tubulointerstitial 
inflammation, morphological and functional changes in 
the glomeruli and renal arteriole and increased salt sen-
sitivity (3,5). There is now sufficient evidence to consider 
increased SUA as an etiological factor in “hyperuricemic hy-
pertension” or “salt-sensitive kindey-dependent hyperten-
sion” (3,5). Clinical and epidemiological studies have linked 
increased SUA to occurrence and outcomes of diabetes 
mellitus, metabolic syndrome, and chronic renal failure 
(3,5,6). It has also been suggested as a risk factor for occur-
rence and a predictor of poorer outcomes in acute stroke 
(7-9) and a risk factor for occurrence/outcomes in vari-
ous aspects of cardiovascular morbidity (3,5,6). However, 
there are also views that SUA is not relevant in the patho-
physiology of cardiovascular diseases and that it should be 
viewed as a secondary side-marker of etiologically relevant 
processes (3,5).
Acute myocardial infarction (AMI) is the most dramatic 
manifestation of the coronary artery disease (CAD) (10). 
High SUA has been indicated as a risk factor for CAD (10) 
and as an independent prognostic factor of poorer out-
comes (occurrence of AMI, fatal AMI, sudden death, all-
cause mortality) in patients with verified CAD (11,12). Less 
is known about SUA as a potential prognostic/risk factor for 
outcomes in patients affected specifically by AMI. A recent 
retrospective analysis from Japan (13) observed a univari-
ate association between higher SUA on admission (within 
48 hours since the symptom onset) and higher thirty-day 
mortality (fourth vs first quartile SUA values) in AMI patients. 
It also reported an independent association between high-
er SUA and poorer long-term survival (13). Having in mind 
potential ethnic/racial specificities and cultural differences 
(eg, diet, alcohol consumption), we aimed to investigate 
SUA levels determined on admission as a potential predic-
tor of short-term mortality (while accounting for relevant 
covariates) and long-term survival in a sample of patients of 
European descent (Caucasians) with verified AMI.
PaTienTS and meThodS
This retrospective prognostic analysis used data from the 
patient database of the Varaždin County General Hospital 
in Varaždin, Croatia and was approved by the institution’s 
Ethics Committee.
Patients
Candidates for inclusion were acute coronary syndrome 
patients admitted to Varaždin County General Hospital 
between 1 January 1996 and 31 December 2001 meeting 
the following criteria: a) to be Caucasians of European de-
scent; b) to have verified AMI (clinical symptoms, typical 
electrocardiographic [ECG] findings on a standard 12-lead 
ECG [new ST-T changes, new left bundle branch block or 
development of pathological Q waves], elevated cardi-
ac biochemical markers [creatin phosphokinase, CPK-MB 
fraction] with or without typical echocardiographic find-
ings [typical new regional wall motion abnormality]); c) to 
have been admitted and laboratory evaluated within 48 
hours from the symptom onset. During the analyzed pe-
riod (1996-2001), troponin levels were not used as a diag-
nostic aid. All source data were (re)evaluated by the same 
investigator (S.C.). Patients who were dead on admission 
were not included. Of the 943 patients alive on admission, 
265 were excluded since AMI could not be verified, 48 due 
to late referral, and 9 due to the late laboratory evaluation. 
This left 621 patients for the analysis.
Standardized in-house procedure for ami
All patients with acute coronary syndromes were handled 
according to a standardized algorithm. On-admission, lab-
oratory evaluation always included serum uric acid (μmol/
L), serum creatinine (Cr, μmol/L), CPK levels (U/L), total cho-
lesterol (mmol/L), and triglycerides (mmol/L). They were 
admitted to the Intensive Care unit (ICU) and were all giv-
en antiplatelet treatment, except where contraindicated. 
In cases of verified AMI with ST elevation, and when indi-
cated, fibrinolytic treatment with streptokinase was com-
menced. During the observed period (1996-2001), primary 
percutaneous interventions were not employed at the in-
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stitution – the method was introduced in 2005 as a part of 
the National Program for Primary Percutaneous Interven-
tions. During the ICU stay, all patients were continuously 
ECG-monitored, whereas oxygenation and other inter-
ventions were performed as needed. Stabilized patients 
were transferred to the Department of Cardiology until 
discharge.
Clinical and laboratory measurements
Standard 12-lead ECG recordings were made using various 
models of Siemens (Erlangen, Germany) ECG apparatuses. 
Integrated biochemical analyzers of the Abbott-Architect 
series (Abbott Park, IL, USA) were used for laboratory mea-
surements of serum uric acid, creatine phosphokinase ac-
tivity, serum creatinine, total cholesterol, and triglycerides.
outcomes
We defined two primary outcomes related to short-term 
mortality (in-hospital and thirty-day) and one secondary 
outcome related to long-term survival (long-term all-cause 
mortality). In-hospital mortality was defined as a propor-
tion of patients who died during the hospital stay initiat-
ed due to the onset of AMI. Thirty-day mortality was de-
fined as a proportion of patients who died within 30 days 
since the symptom onset, either during the initial hospital 
stay or after discharge. In the case of out-of-the hospital 
deaths, death dates were verified from death certificates. 
Since mortality rate during the first 30 days after the index 
event in AMI patients is by far higher than during any oth-
er subsequent 30-day period, only patients surviving the 
first 30 days were considered for the analysis of long-term 
survival/all-cause mortality, and day 30 post index event 
was considered as “time 0” for determination of “time-to-
event.” All patients were contacted by phone or in writing. 
When it was confirmed that they were alive, this date was 
used to calculate “censored time.” If no confirmation was 
received, community death registers were searched to 
verify the date of death and calculate the “failure time.” For 
patients who did not respond to our attempts to contact 
them and for whom death date could not be determined 
through a search of the community death register, the last 
documented date of a control visit was used to determine 
“censored time.”
Statistical analysis
Due to data skewness, all continuous variables are summa-
rized as medians (ranges). In-hospital and thirty-day mor-
tality were analyzed using modified Poisson regression 
with robust error variance to obtain adjusted incidence ra-
tios, ie, relative risk (RR) rather than odds ratio since data 
were collected prospectively and event rates were relative-
ly high (≥10%) (14). “Time-to-event” data were analyzed by 
fitting proportional hazard regression models with the ex-
act method for ties. On-admission SUA levels as a depen-
dent variable were analyzed using multiple linear regres-
sion. Residuals were normally distributed. We used SAS for 
Windows software, version 9.1.3. (SAS Inc., Cary, NC, USA) 
licensed to Zagreb University School of Medicine.
ReSulTS
Patients’ characteristics
Patient characteristics are summarized in Table 1. Cardio-
vascular treatments utilized before the index event includ-
ed angiotensin converting enzyme inhibitors (25.3%), cal-
cium channel blockers (21.7%), nitrates (21.6%), diuretics 
(14.7%), antiplatelets (13.9%), digitalis (8.5%), beta blockers 
(5.8%), and statins (2.7%). Patients were admitted between 
Table 1. Patient characteristics and short-term mortality 
(n = 621)
Characteristic data†
Men 402 (64.7)
Time: symptom onset to admission (hours)   6 (0.5-48)
STEMI/NSTEMI 481 (77.5)/140
Right bundle branch block  22 (3.5)
Left bundle branch block  20 (3.2)
Age (years)  65 (27-91)
Current smokers 208 (33.5)
Prior acute myocardial infarction  94 (15.1)
Prior cerebrovascular insult  57 (9.2)
Prior angina 126 (20.3)
Prior by-pass, stent or PTCA   9 (1.4)
Prior hypertension 459 (73.9)
Prior symptomatic heart failure  61 (9.8)
Diabetes mellitus 129 (20.8)
Serum uric acid on admission (µmol/L) 315 (63-993)
Serum creatinine on admission (µmol/L) 105 (43-804)
Serum triglyceride on admission (mmol/L)   1.24 (0.22–16.9)
Serum total cholesterol on admission (mmol/L)  5.34 (1.6 –11.3)
Peak creatine phosphokinase (U/L) 771 (0-9350)
Fibrinolytics after index event  48 (7.7)
In-hospital mortality  62 (9.98)
Thirty-day mortality  77 (12.4)
*abbreviations: STemi – myocardial infarction with ST elevation; 
nSTemi – myocardial infarction without ST elevation; PTCa – percuta-
neous transluminal coronary angioplasty.
†data are counts (%) or medians (ranges).
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0.5 and 48 hours after the symptom onset and SUA values 
on admission varied between 63 and 993 µmol/L. In a mul-
tivariate analysis (Table 2), higher SUA levels were associat-
ed with higher serum creatinine, male sex, history of heart 
failure, and history of cerebrovascular insult. Smokers had 
lower SUA than non-smokers (Table 2).
Sua and short-term mortality
In-hospital mortality was 9.98% and thirty-day mortality 
was 12.4% (Table 1). There was a clear-cut univariate asso-
ciation between higher SUA levels and higher in-hospital 
and thirty-day mortality (Figure 1). For multivariate anal-
ysis, a regression model was first built for each outcome 
using a stepwise procedure and then variables associated 
with higher SUA (depicted in Table 2) and AMI type were 
forced into the models, if not already included. With all the 
adjustments, higher SUA levels were independently as-
Table 2. multivariate analysis of serum uric acid on admission 
(n = 621)*
Variables estimate (95% Ci)† P
Serum creatinine    0.77 (0.61-0.94) <0.001
Male sex   28.4 (8.59-48.2)   0.005
Prior symptomatic heart failure   73.1 (42.4-104) <0.001
Prior cerebrovascular insult    41.0 (9.77-72.3)   0.010
Current smoker -26.9 (-47.3 to -6.54)   0.009
*linear regression analysis, using stepwise selection proce-
dure with P < 0.05 to enter and P < 0.10 to stay in the model 
was employed. Potential independents: demographic and 
pre-index event medical history data and laboratory variables 
determined on admission.
†estimates are given with 95% confidence intervals (Ci).
Figure 1.
univariate association between serum uric acid levels on admission and 
in-hospital and thirty-day mortality in acute myocardial infarction pa-
tients (n = 621). estimated probabilities are from logit models with se-
rum uric acid as a single continuous independent. Relative risk (RR) per 
10 units change in uric acid levels with 95% confidence intervals (Ci) is 
from modified Poisson regression with robust error variance with serum 
uric acid as a single independent. Solid line – in-hospital mortality (RR, 
1.038; 95% Ci, 1.026-1.051); dashed line – thirty-day mortality (RR, 1.035; 
95% Ci, 1.024-1.047).
Table 3. multivariate analysis of in-hospital and thirty-day mortality in acute myocardial infarction patients (n = 621)*
Relative risk (95% confidence interval)†
independent variables in-hospital mortality P thirty-day mortality P
Serum UA (10 units) 1.016 (1.001-1.031)   0.043 1.016 (1.003-1.029)   0.018
Male sex 0.568 (0.346-0.933)   0.026 0.646 (0.427-0.978)   0.038
Age 1.040 (1.020-1.061) <0.001 1.043 (1.025-1.061)  <0.001
Prior CVI 2.016 (1.173-3.465)   0.011 2.309 (1.515-3.520) <0.001
Prior hypertension 0.564 (0.324-0.981   0.043 0.622 (0.389-0.994)   0.047
Peak CPK (10 units) 1.001 (1.000-1.003)   0.096 1.001 (1.000-1.002)   0.068
RBBB 3.029 (1.322-6.941)   0.009        –    –
Prior AMI 2.200 (1.256-3.852)   0.006        –    –
Serum Cr (10 units)‡ 1.025 (1.001-1.049)   0.045 1.019 (0.995-1.044)   0.118
Prior heart failure§ 1.305 (0.687-2.479)   0.416 1.523 (0.911-2.544)   0.108
STEMI§ 1.433 (0.765-2.685)   0.262 1.267 (0.781-2.155)   0.316
*abbreviations: ua – uric acid; CVi – cerebrovascular insult; CPK – creatine phosphokinase; Rbbb – right bundle branch block; ami – acute myocar-
dial infarction; Cr – creatinine; STemi – myocardial infarction with ST elevation.
†Statistics: modified Poisson regression with robust error variance. a model was first built for each outcome using a stepwise selection procedure 
(P < 0.05 to enter, P < 0.10 to stay in the model) and then variables associated with higher serum uric acid on admission (depicted in Table 2) and 
infarction type were forced into the model, if not already included. Potential independents (depicted in Table 1): demographics, pre-index event 
medical history and treatment, laboratory variables determined on admission, myocardial infarction characteristics.
‡Forced into the model explaining variability of thirty-day mortality.
§Forced into both models.
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sociated with both higher in-hospital mortality (RR by 10 
units, 1.016; 95% CI, 1.001-1.031, P = 0.043) and higher thir-
ty-day mortality (RR by 10 units, 1.016; 95% CI, 1.003-1.029, 
P = 0.018) (Table 3).
Sua and long-term survival (all-cause mortality)
Characteristics of patients who survived the first 30 days af-
ter AMI and were evaluated for long-term survival (n = 544) 
are summarized in Table 4. The shortest observed censored 
time was 207 days (after day 30 post-index event) and the 
longest one was 13 years. A total of 175 (32.2%) deaths 
were observed, the first one 3 days after day 30 post-index 
event and the last one 10 years later. There was a clear-cut 
univariate association between higher SUA on admission 
and poorer long-term survival (higher all-cause mortality) 
(Figure 2). Multivariate analysis indicated a significant in-
dependent association of higher SUA and poorer survival 
(HR by 10 units, 1.105; 95% CI, 1.020-1.195, P = 0.010), which 
was conditional on age (significant SUA/age interaction) 
(Table 5). This is also illustrated by separate multivariate 
Table 4. Patients surviving the first 30 d after acute myocar-
dial infarction and considered for long-term survival analysis 
(n = 544)*
Characteristic data†
Men  367 (67.5)
STEMI/NSTEMI  418 (76.8)/126
Age (years)  63 (27-90)
Serum uric acid on admission (µmol/L) 312 (63-827)
Serum creatinine on admission (µmol/L) 104 (43-804)
Serum triglyceride on admission (mmol/L)    1.26 (0.22-16.9)
Serum total cholesterol on admission (mmol/L)   5.44 (1.67-11.3)
Diabetes mellitus  109 (20.0)
Hypertension  412 (75.7)
History of cerebrovascular insult   40 (7.35)
in-hospital maCe:
symptomatic heart failure  149 (27.4)
ventricular tachycardia/fibrillation  147 (27.0)
atrial fibrillation/undulation   52 (9.6)
re-infarction or angina   33 (6.1)
atrio-ventricular block   26 (4.8)
Treatment at discharge:
antiplatelets  445 (81.8)
nitrates  440 (80.9)
ACE inhibitors  342 (62.9)
diuretics  234 (43.0)
beta blockers  141 (25.9)
statins   84 (15.4)
calcium channel blockers   69 (12.7)
digitalis   39 (7.2)
observed period after day 30 post index 
event (days)
censored observations 2525 (207-4715)
deaths  730 (3-3615)
all-cause mortality during the observed period  175 (32.2)
*abbreviations: STemi/nTSemi – myocardial infarction with/ without 
ST elevation; maCe – major adverse cardiac events; aCe – angiotensin 
converting enzyme.
†data are presented as counts (%) or medians (ranges).
Table 5. multivariate analysis of time to death (all-cause) in 
544 acute myocardial infarction patients who survived the first 
30 d after the index event*
 
independent variables
hazard ratio 
(95% confidence interval)
 
P
Serum uric acid on admission 
(10 units)
1.105 (1.020, 1.195)   0.010
Serum creatinine on admission 
(10 units)
1.041 (1.010, 1.061)   0.003
Symptomatic heart failure at 
discharge
1.767 (1.260, 2.478)   0.001
Age 1.099 (1.054, 1.145) <0.001
Use of digitalis after discharge 1.704 (1.081, 2.685)   0.022
Serum uric acid/age† 0.999 (0.998, 1.000)   0.017
*Proportional hazard regression with exact method for ties. 
Stepwise procedure with P < 0.05 to enter and P < 0.10 to stay 
in the model was employed. Potential independents (Table 4): 
demographic data, laboratory variables determined on admis-
sion, myocardial infarction characteristics and acute complica-
tions, treatment at discharge.
†interaction term.
univariate association between serum uric acid (Sua) levels on admis-
sion and long-term survival (after 30 days post index event) in acute my-
ocardial infarction (ami) patients (n = 544). Survival probability was esti-
mated in a proportional hazard regression model with Sua on admission 
as an independent variable. hazard ratio (by 10 units) of Sua, 1.027; 95% 
confidence interval, 1.015-1.039.
Figure 2.
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analyses in patients younger than the median age (age 27-
63 years, n = 274) and patients older than the median age 
(>63-90 years, n = 270) (Figure 3): higher SUA was indepen-
dently associated with poorer survival in the former (HR by 
10 units, 1.030; 95% CI, 1.009-1.051, P = 0.021) but not in the 
latter (HR by 10 units, 1.004; 95% CI, 0.991-1.017, P = 0.575).
diSCuSSion
Our study demonstrated that higher serum uric acid deter-
mined on admission is associated with higher in-hospital 
mortality and thirty-day mortality and poorer long-term 
survival after AMI.
The (wide) range of SUA levels determined on admission 
in the current cohort was practically identical to that ob-
served in Japanese AMI patients (13) (all within 48 hours 
since the symptom onset) and the observed cross-sec-
tional associations were expected considering pre-
vious knowledge (1,3,4,13). Currently, SUA is generally not 
considered a relevant factor in the assessment of risk/pre-
diction of outcomes in AMI patients (3,15). The main find-
ing of the present study in a sample of Caucasians of Euro-
pean descent is that higher SUA determined on admission 
(within 48 hours since the symptom onset) predicts higher 
in-hospital and thirty-day mortality after AMI. The results 
are in line with those in Japanese patients (13) and add 
to the observation that the relationship is independent, 
ie, not confounded by other factors influencing mortality 
and/or actual SUA levels. This is particularly interesting re-
garding serum creatinine because a) higher serum creati-
nine on admission is a well-accepted predictor of mortal-
ity after AMI (15) and b) just like others (13), we found an 
independent cross-sectional association between higher 
serum creatinine and higher SUA. The latter observation 
appears logical since both UA and creatinine are eliminat-
ed by the kidney. The present results suggest that in AMI 
patients, like in non-AMI CAD patients (11), the “risk” as-
sociated with SUA is separated from the “risk” attributable 
to serum creatinine, indicating renal function. Moreover, 
considering the adjusted RRs of in-hospital and thirty-day 
mortality (Table 3), risk increase associated with 10-unit 
(µmol/L) increase in SUA is not much different from that 
associated with 10-unit (µmol/L) increase in serum creati-
nine. Consequently, it appears reasonable to suggest that 
risk stratification systems for AMI patients, like GRACE (15), 
could benefit from inclusion of SUA in addition to serum 
creatinine (and other elements), particularly as it is a cheap 
marker that is readily, quickly, and reliably obtainable. By 
saying that, we do not neglect the fact that the present 
study, just as the Japanese one (13), suffers from limitations 
inherent to its retrospective nature, primarily susceptibility 
to bias (selection, treatment, assessment). However, we be-
lieve that the characteristics of the analyzed setting (AMI is 
an acute serious condition that is “handled” in standardized 
ways in ICUs where patients are continuously and close-
ly followed-up and data are collected prospectively) and 
clear and simple inclusion and evaluation criteria that we 
used minimized potential biases. Therefore, we consider 
that the present estimates have achieved a reasonable lev-
el of internal validity. However, their generalizability is limit-
ed by the fact that they refer to AMI patients treated exclu-
sively conservatively in the late 1990s and that, therefore, 
the established relationships might not be fully applicable 
to up-to-date settings with treatment strategies combin-
ing novel pharmacological and invasive procedures. Oth-
er effects on short-term mortality are difficult to interpret 
since they were not the primary objective of the study: the 
goal was not to find the best set of explanatory variables or 
Figure 3.
multivariate analysis of time to death (all-cause) in acute myocardial 
infarction (ami) patients who survived the first 30 days after the index 
event and were either younger (age 27-63 years) or older (>63 years) 
than the median age. a separate proportional hazard regression model 
was built for each subgroup. Serum uric acid (Sua) levels were included 
in both models, whereas other effects were selected using a stepwise 
procedure (P < 0.05 to enter, P < 0.10 to stay in the model). Potential in-
dependents were the same as in analysis shown in Table 5. open circles – 
age 27-63 years, n = 274, 46 deaths. adjusted hR for Sua (10 units), 1.030; 
confidence interval, 1.009-1.051, P = 0.021 (symptomatic heart failure 
at discharge, post-ami ventricular tachycardia or fibrillation, and use 
of digitalis after discharge). Closed circles – age >63 years, n = 270, 129 
deaths. adjusted hR for Sua (10 units); confidence interval, 0.991-1.017, 
P = 0.575 (serum creatinine on admission, symptomatic heart failure at 
discharge, use of beta blockers, and use of nitrates after discharge).
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to evaluate all possible effects, but to test the hypotheses 
about SUA. Consequently, covariate selection was guided 
by previous knowledge and by statistical significance with-
in the current sample. Non-inclusion or “insignificance” of a 
particular variable in the present models does not mean 
that it might not, in general, have an impact on outcomes 
after AMI, particularly if the effect is small or associated 
with a relatively infrequent patient/disease-related char-
acteristic. Bundle branch blocks (BBB) are illustrative in 
this respect. In the present sample, only 22 (3.5%) patients 
had right BBB (RBBB) (either at presentation or during the 
hospital stay) and 20 (3.2%) had left BBB (LBBB). The for-
mer was independently associated with higher in-hospital 
mortality, whereas the latter was not. A meticulous analy-
sis of 17 073 AMI patients (16) found a similar prevalence of 
LBBB and RBBB but the absolute numbers were almost 20 
times higher. Newly developed LBBB was associated with 
higher 30-day mortality, whereas independent associa-
tion was found for both “presenting” and newly developed 
RBBB (conditional on AMI localization) (16). Such a detailed 
analysis of BBB impact (or any other factor besides SUA) on 
AMI outcomes was beyond the scope of the present study. 
Hence, our results do not “eliminate” LBBB as irrelevant in 
general. At the same time, lack of an independent effect of 
LBBB does not compromise the conclusion about the in-
dependent effect of SUA. The same principle applies to the 
analysis of the secondary outcome, which confirmed ob-
servations from the Japanese study (13) about higher SUA 
as an independent predictor of higher long-term all-cause 
mortality after AMI. It should be noted, however, that SUA 
varies over time and is susceptible to various influences. 
Hence, it should be preferably treated as a time-varying co-
variate (which is almost never the case), and “predictivity” 
based on a single-point measurement might not be too 
informative. In the present cohort, the “effect” of SUA was 
independent of but conditional on age, ie, was apparent 
in “younger” patients but not in the “older” ones. We argue 
that this is due to inherently much higher hazard rates in 
the latter subgroup. Looking at the entire cohort, however, 
the “effect” of SUA was but small: the reported HR by 10 
units increase corresponded to an HR of around 1.65 by 50 
units increase and this is comparable to an HR by 5 years 
increase in age (around 1.60) or to that for “symptomatic 
heart failure at discharge” (around 1.77). Heart failure is a 
known prognostic factor of poor long-term outcomes af-
ter AMI with a “dose-dependent” effect (more severe the 
condition [eg, higher the Killip’s class], poorer the surviv-
al) (13) but we could not “grade” it. However, the effect of 
a more severe failure might have been aliased by “use of 
digitalis at discharge;” digitalis is typically used in more se-
vere patients, but per se has no impact on long-term sur-
vival (17), and 36/46 of the present “30-day survivors” who 
were prescribed with digitalis at discharge were diagnosed 
with symptomatic heart failure at the same time. Finally, 
from the today’s perspective (15), the use of beta-blockers 
in long-term treatment of “30-day survivors” in the present 
cohort was seemingly lower than “optimal” (25.9% were 
prescribed with beta-blockers at discharge). We have no 
explanation for this observation, which apparently reflects 
the practice from 10-13 years ago. Underuse of beta-block-
ers may affect long-term survival (12), but we find it un-
likely that this fact biased the observations related to SUA 
– present observations are fully in line with those from a 
more recent Japanese cohort (13).
To conclude, higher SUA determined on admission (within 
48 hours since the symptom onset) in a cohort of patients 
from Croatia was independently associated with higher 
short-term mortality and poorer long-term survival after 
AMI. The findings are in agreement with the observations 
in Japanese patients (13) and document relevance of on-
admission SUA for risk stratification in AMI patients.
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